EUVIMEDEUVIMED entdecken
Crossref

Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer

Abu Sufiyan Chhipa, Margherita Gallicchio, Valentina Boscaro, Snehal Patel

European Journal of Pharmacology · 2025-12 · 1008 · 178249

DOI: 10.1016/j.ejphar.2025.178249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025-12. Verfasst von Abu Sufiyan Chhipa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Nirma University, Ahmedabad, India; Department of Drug Science and Technology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms, Tilorone, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tilorone is an orally active antiviral interferon inducer with anticancer effects. Doxorubicin has been previously reported to exhibit synergism with type 1 interferons. The present study investigated the anticancer effects of doxorubicin in combination with tilorone in breast cancer. METHODS: Effects of different concentrations of tilorone (5μM-80μM) and doxorubicin (0.03μM-32μM) on the viability of breast cancer cells (MDA-MB-231 and MDA-MB-468) were measured by MTT assay. For combination studies, drugs were combined in equipotent ratios. CompuSyn analysis was performed to determine the synergistic combinations (CI < 1). Colony formation and Western blot assays were performed to measure proliferation and apoptosis. In vivo efficacy of the combination was tested in the DMBA-induced breast cancer model. After 3 weeks of treatment, tumors were excised for tumor-specific and immunohistochemical analysis. CompuSyn analysis was applied to assess in vivo drug interactions. RESULTS: Combination of equipotent doses of tilorone and doxorubicin synergistically (CI < 1) caused significant reduction in cell viability with an increase in the pro-apoptotic proteins at the combination of IC50/2, IC50, and, 2 × IC50 dose combinations of doxorubicin and tilorone in comparison to single drug treatments. The combination of doxorubicin and tilorone also exhibited synergism in DMBA-induced breast cancer at all tested dose combinations. Tumor tissue showed increased expression of IFN-β, caspase-3, P53, and E-cadherin with decreased N-cadherin expression in treatment groups, with more prominent changes observed in combination groups. Medium dose combination of tilorone and doxorubicin (T2D2) most effectively inhibited tumor progression with reduced hepatic and renal toxicities. CONCLUSION: Doxorubicin in combination with tilorone exerts synergistic effects against breast cancer with reduced side effects. The combination can be further explored in clinical settings for effective management of breast cancer with reduced side effects caused by doxorubicin chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinBreast NeoplasmsTiloroneAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsDrug SynergismHumansFemaleAnimalsCell Line, TumorApoptosisCell ProliferationMiceCell SurvivalXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ApoptosisBreast cancerDoxorubicinE-CadherinSynergismTilorone

Substanzen

DoxorubicinTiloroneAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Pharmacy, Nirma University, Ahmedabad, India; Department of Drug Science and Technology, University of Turin, Turin, Italy.
  • Department of Drug Science and Technology, University of Turin, Turin, Italy.
  • Institute of Pharmacy, Nirma University, Ahmedabad, India. Electronic address: snehalpharma53@gmail.com.

Förderung

  • Department of Science and Technology

Zitieren

APA

Chhipa, A. S., Gallicchio, M., Boscaro, V., & Patel, S. (2025). Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer. European Journal of Pharmacology, 1008, 178249. https://doi.org/10.1016/j.ejphar.2025.178249

Vancouver

Chhipa AS, Gallicchio M, Boscaro V, Patel S. Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer. European Journal of Pharmacology. 2025;1008:178249. doi:10.1016/j.ejphar.2025.178249

BibTeX
@article{Chhipa2025,
  author = {Chhipa, Abu Sufiyan and Gallicchio, Margherita and Boscaro, Valentina and Patel, Snehal},
  title = {Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer},
  journal = {European Journal of Pharmacology},
  year = {2025},
  volume = {1008},
  pages = {178249},
  doi = {10.1016/j.ejphar.2025.178249}
}
Kostenlos starten →